Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Lerner Neil, holds the title of Chief Accounting Officer at Compass Therapeutics, Inc..
On 2026-11-17, the insider transacted 10,000 shares.The shares were transacted at a weighted average price of $0.59 per share, resulting in a total market-relevant value of $6K.
Lerner Neil (Chief Accounting Officer) bought $6K of $CMPX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.